Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Periorbital Infections : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Angioedema

Bites, Insects

Cavernous Sinus Thrombosis

Chalazion

Hordeolum and Stye

Orbital Infections




Patient Education
Diabetes Center

Cellulitis Overview

Cellulitis Causes

Cellulitis Symptoms

Cellulitis Treatment




Author: R Gentry Wilkerson, MD, Clinical Assistant Professor, Department of Emergency Medicine, State University of New York-Downstate; Attending Physician, Department of Emergency Medicine, Kings County Hospital

R Gentry Wilkerson is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians

Coauthor(s): Richard Sinert, DO, Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center; Zach Kassutto, MD, FAAP, Director, Pediatric Emergency Medicine, Capital Health System; Associate Professor of Pediatrics and Emergency Medicine, Drexel University College of Medicine; Attending Physician, St Christopher's Hospital for Children; Elizabeth Fiedler, MD, Clinical Instructor, Department of Emergency Medicine, Montefiore Medical Center - Weiler Division

Editors: Edmond A Hooker II, MD, DrPH, FAAEM, Assistant Professor, Department of Health Services Administration, Xavier University; Associate Clinical Professor, Department of Emergency Medicine, University of Louisville; Assistant Clinical Professor, Department of Emergency Medicine, Wright State University; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Douglas Lavenburg, MD, Clinical Professor, Department of Emergency Medicine, Christiana Care Health Systems; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School

Author and Editor Disclosure

Synonyms and related keywords: periorbital infection, periorbital cellulitis, preseptal cellulitis, blepharitis, eyelid inflammation, lacrimal gland inflammation, hordeolum, stye, dacryoadenitis, dacryocystitis, canaliculitis



Background

Periorbital infections comprise a group of infections that can be broadly classified into two distinct groups. One group consists of infections of the dermis and associated tissues around the eyes. The other group consists of infections of the lacrimal system.

Infections of the superficial skin around the eyes are called periorbital or preseptal cellulitis. These infections are limited to the area anterior to the orbital septum. The orbital septum is a fibrous membrane that extends from the periosteum of the orbit as the arcus marginalis and lies just deep to the orbicularis oculi muscle. In the upper lids, the septum fuses with the levator aponeurosis. In the lower lids, the septum fuses with the capsulopalpebral fascia.1 The orbital septum acts as a physical barrier to the spread of infection.

Infections of the lacrimal system are classified based on the location of the infection. The lacrimal system includes the structures involved in production and drainage of tears. The lacrimal gland is located in the lateral upper lid margin. It produces about 10 mL of secretions per day. In the process of blinking, the eyes close from lateral edge to the medial edge pushing the tear film across the surface of the eye. Most of the tear volume is lost by evaporation. A small portion is drained from the lacrimal lake located at the inner canthus through the puncta and into the superior and inferior canaliculi. Tears then flow into the common canaliculus and lacrimal sac. The lacrimal duct, which lies within the bone, connects the lacrimal sac with the eventual site of egress, the inferior meatus of the nose.1

Blepharitis is an inflammation of the lid margins. Anterior blepharitis affects the area of the lid where the eyelashes attach. Posterior blepharitis affects the inner portion of the eyelid margin that is in contact with the eye.

Dacryoadenitis is inflammation of the lacrimal gland. Dacryocystitis is inflammation of the lacrimal duct or sac. Canaliculitis is inflammation of the canaliculi.

Pathophysiology

Periorbital cellulitis

Periorbital cellulitis can occur by several mechanisms.

  • Infection as a result of local trauma including insect bites
  • Infection as a result of spread from contiguous structures such as in conjunctivitis, hordeolum, lacrimal system infections, and impetigo
  • Infections secondary to hematogenous spread during bacteremia due to nasopharyngeal pathogens
  • Infections secondary to sinusitis causing venous and lymphatic congestion: The sinusitis may be of odontogenic origin.2 A thorough examination of dentition may be warranted.

Blepharitis

  • Anterior blepharitis is usually caused by bacteria that colonize the base of the eyelashes. If the pilosebaceous glands of Zeiss and Moll become infected an abscess will occur. This abscess is known as an external hordeolum or stye.3 Cell-mediated immunologic mechanisms have been implicated in the development of chronic blepharitis.4
  • Posterior blepharitis is caused by Meibomian gland dysfunction. The Meibomian gland secretes an oily layer of the tear film. If the secretions become inspissated, causing plugging of the gland, a chalazion may develop. A chalazion is a noninfectious granulomatous reaction. If there is infection secondary to plugging, an internal hordeolum develops.5

Dacryoadenitis

  • Dacryoadenitis is caused by local infection of the lacrimal gland by bacteria or viruses.
  • Dacryoadenitis associated with inflammation and swelling of the salivary glands is called Mikulicz syndrome. This is considered a subtype of Sjögren syndrome.6

Dacryocystitis

  • Dacryocystitis is caused by inflammation of the lacrimal sac; this usually occurs in the setting of obstruction of the lacrimal apparatus.
  • The obstruction may be congenital, secondary to infection, tumor, or trauma.1

Canaliculitis

  • Canaliculitis is caused by infection of the canaliculi; usually, it is chronic.
  • It may also be iatrogenic after instrumentation or placement of silicone plugs in the treatment of dry eyes.7

Sex

No gender predominance exists.

Age

Periorbital cellulitis is predominantly a pediatric disease.8

Obstructed lacrimal ducts causing dacryocystitis are common in infants and usually resolve by age 9-12 months.9

Blepharitis affects primarily older persons, with a mean age of 50 years.



History

  • Periorbital cellulitis
    • An antecedent history of insect bite, trauma to the periorbital skin, infection of adjacent structures, upper respiratory infection, or sinusitis may be present.
    • A sudden increase in temperature and rapid swelling of tissue may occur.
    • A history of underlying illness (eg, HIV acute lymphoblastic leukemia), which would increase the patient's risk of infection, may be present.
  • Anterior blepharitis
    • Erythema, pruritus, and crusting of lid margins
    • Typically without discharge
  • Posterior blepharitis
    • Epiphora
    • Foreign body or burning sensation10
    • Blurred vision, photophobia
  • Dacryoadenitis
    • Swelling of upper lateral eyelid
    • Scleral injection
    • If caused by a viral infection, the area is modestly tender. Bacterial causes result in more severe tenderness.
  • Dacryocystitis
    • A history of chronic conjunctivitis or recent upper respiratory infection may be present.
    • Epiphora
    • Fever
    • Swelling, tenderness, and erythema usually localized of the medial canthal area
    • Purulent discharge
  • Canaliculitis
    • Epiphora
    • Irritation or pruritus of medial portion of affected eyelid

Physical

  • Periorbital cellulitis
    • Erythema, swelling, and tenderness of the lids without evidence of orbital congestion (proptosis, decreased extraocular movement)
    • Fever
    • Vesicles if associated with herpetic infection
    • Violaceous discoloration of the lid is more commonly associated with Haemophilus influenzae but may be associated with infection with Streptococcus pneumoniae.11
    • If associated with trauma, there may be a break in the skin overlying the area of cellulitis.
  • Anterior blepharitis
    • Crusting at the base of the lash (known as scurf or collarettes), erythema of lid
    • Usually, no discharge
    • Poliosis, or whitening of the lash, may occur.3
    • If associated with ocular rosacea, telangiectatic vessels may be noted on the lid margins and cheeks.12
    • In chronic cases, ulceration of the lid, lid notching (tylosis), thinning of eyelashes (madarosis), or misdirection of the eyelashes (trichiasis) may be noted.
  • Posterior blepharitis 
    • Decreased Schirmer score
    • Conjunctival hyperemia13
  • Dacryoadenitis
    • Soft tissue swelling that is greatest at the lateral portion of the upper lid margin14
    • Deforms the upper lid into a characteristic S-shape9
    • If caused by a viral infection, the area is modestly tender. Bacterial causes result in more severe tenderness.15
    • Decreased Schirmer score
  • Dacryocystitis: Pressure on the area overlying the lacrimal sac may cause expression of purulent material from the lacrimal puncta.
  • Canaliculitis
    • Edematous, "pouting" punctum
    • Erythema of adjacent conjunctiva
    • Mucous regurgitation from punctum on application of pressure
    • Yellowish concretions may be expressed from the punctum. These are sulfur granules produced by Actinomyces israelii.

Causes

  • Periorbital cellulitis16
    • When associated with trauma
      • Staphylococcus aureus: This may include methicillin-resistant Staphylococcus aureus17 and treatment should be tailored to local incidence of infection. 
      • Streptococcus pyogenes (group A streptococci)
    • In the absence of trauma
      • Streptococcus pneumoniae
      • H influenzae type b was the predominant cause prior to the advent of the Hib vaccine but has now only been shown to cause rare cases.8, 18, 19, 20
    • Other unusual causes 
      • Neisseria gonorrhoeae21
      • Neisseria meningitidis22, 23
      • Vaccinia virus24 in a laboratory worker has been reported. Autoinoculation in patients receiving the vaccine has been reported.25
      • Herpes simplex virus
      • Mycobacterium tuberculosis26
      • Bacillus anthracis27
  • Blepharitis
    • Anterior blepharitis
      • Almost exclusively caused by Staphylococcus species3
      • Other bacteria include Propionibacterium acnes and Moraxella species.9
      • Helicobacter pylori is associated with blepharitis; however, cause and effect has not been established.28
      • Viruses - Herpes simplex virus, herpes zoster virus, and human papillomavirus
      • Mites - Demodex folliculorum and Demodex brevis29
      • Lice - Phthirus pubis causing the condition known as phthiriasis palpebrarum30
      • Noninfectious entities such as ocular rosacea and seborrheic dermatitis may also cause anterior blepharitis.
    • Posterior blepharitis - Meibomian gland dysfunction
  • Dacryoadenitis
    • Bacteria – This is most often caused by gram-positive cocci, usually staphylococci. It may also be caused by Streptococcus pneumoniae.
    • Viruses - Prior to increased immunization rates, the mumps virus was most often implicated. Now, the Epstein-Barr virus is most often associated with chronic dacryoadenitis.31
  • Dacryocystitis
    • Dacryocystitis usually occurs as a result of obstruction of the lacrimal system, which may be congenital, infectious, tumor, inflammatory, or traumatic.
    • Infectious causes include most commonly gram-positive isolates in 78% (Staphylococcus and Streptococcus species) and gram-negative isolates in 22%.32
  • Canaliculitis
    • It is classically taught that the most common pathogens of canaliculitis are Actinomyces israelii and Nocardia (formerly known as Streptothrix) species.9
    • Recent case reviews have shown mixed flora associated with infection. Species isolated include Staphylococcus species, Escherichia coli, Haemophilus species, Pseudomonas aeruginosa, Klebsiella oxytocia,33 Arcanobacterium (previously Corynebacterium) haemolyticum, and Mycobacterium chelonae.34
    • Iatrogenic - Instrumentation or plugging



Angioedema
Bites, Insects
Cavernous Sinus Thrombosis
Chalazion
Hordeolum and Stye
Orbital Infections

Other Problems to be Considered

Periorbital cellulitis

  • Angioedema
  • Bites, insect
  • Cavernous sinus thrombosis
  • Chalazion
  • Internal and external hordeola
  • Idiopathic orbital inflammation, also known as orbital pseudotumor35
  • Mucormycosis
  • Nephrotic syndrome
  • Orbital cellulitis
  • Pott puffy tumor36
Blepharitis37

Dacryoadenitis

Canaliculitis

  • Carcinoma39
  • Melanoma



Lab Studies

  • Periorbital cellulitis
    • Complete blood count (CBC) with differential is not routinely necessary. It may be helpful if bacteremia or sepsis is a concern.
    • Blood cultures may be performed if bacteremia or sepsis is a concern.
    • Skin culture has a very low yield.
  • Dacryoadenitis
    • CBC with differential and blood culture may be performed if bacteremia or sepsis is a concern.
    • Serology testing may be indicated if a viral etiology needs to be established.
  • No laboratory studies are indicated for routine use in dacryocystitis, blepharitis, and canaliculitis.

Imaging Studies

  • Periorbital cellulitis
    • Computed tomography (CT) of the orbits should be performed to rule out orbital and subperiosteal involvement and cavernous sinus thrombosis. CT also helps to distinguish sinusitis as cause.
    • Indications for CT include inability to perform a full evaluation of the eye due to edema or patients with proptosis, ophthalmoplegia, decreased visual acuity or color vision, bilateral periorbital edema, or central symptoms.40 
    • CT will show lid edema but no proptosis or "streaking" of the orbital fat, which lies posterior to the orbital septum.
    • MRI is the study of choice to rule out cavernous sinus thrombosis.
    • Patients whose condition fails to improve after 24-36 hours of appropriate antimicrobial therapy should also have CT performed.40
  • Canaliculitis: 20-MHz ultrasound can be used to detect sulfur granules within the canaliculi.41

Procedures

  • Periorbital cellulitis: If infection with H influenzae type b or Streptococcus pneumonia is suspected or if systemic involvement is present, a lumbar puncture is indicated to exclude meningeal infection.
  • Blepharitis: Biopsy may be indicated in some cases to rule out malignancy.
  • Dacryoadenitis: Lacrimal gland biopsy may be indicated in chronic disease.
  • Schirmer test is used to assess tear production. It is nonspecific as to the etiology of dry eyes.
  • Jones dye test is used to assess patency of the lacrimal drainage system. In the first part of the test, a drop of fluorescein is placed in the conjunctival cul-de-sac. After 5 minutes, the nose is examined for the presence of dye. If no dye is present, an obstruction is present and the second part of the test is performed. A cannula is placed into the lacrimal sac, which is then washed with saline. If no fluorescein is noted, the dye is obstructed in the upper (canalicular) portion of the system. If dye is present, then the obstruction is in the lower (sac, duct) portion.42



Emergency Department Care

  • Periorbital cellulitis
    • In adult patients who are nontoxic and can be assured of appropriate follow-up, treatment can be with oral antibiotics on an outpatient basis.
    • Most pediatric patients require admission. Intravenous antibiotics should be started. Once clinical improvement is noted, the patient should be switched to oral antibiotics.
    • Patients who undergo outpatient treatment should be seen daily to ensure clinical improvement.
    • Nasal decongestants may be used for the short term to reduce mucosal edema.40
    • A Clinical Severity Index has been established for periorbital cellulitis in children. It uses systemic features of interaction and fever and local features of location, erythema, extent, and pain and tenderness.43
  • Blepharitis
    • The treatment of blepharitis, regardless of etiology, begins with eyelid hygiene. The patient should be instructed to wash the lids with a nonirritating baby shampoo or a commercially prepared lid scrubbing solution and to use warm compresses for 15 minutes at a time, 3 or 4 times a day.
    • For blepharitis suspected to be infectious in nature, a topical antibiotic, such as bacitracin or erythromycin, should be prescribed. The frequency and duration of treatment should be determined based on the severity of the disease process.44 Usually, it is applied 2-4 times a day for 2 weeks.
    • Posterior blepharitis may be treated with an oral tetracycline, which decreases lipase production in staphylococci preventing plugging of Meibomian glands. This therapy is limited to patients older than8 years due to the risk of tooth enamel discoloration.44 Alternative treatment with the macrolide, erythromycin, is safe for use in children younger than 8 years.45
    • Topical cyclosporine has shown benefit in treatment of posterior blepharitis in a small study of 30 patients compared to treatment with tobramycin/dexamethasone.
    • A brief course of preservative-free topical steroids has been shown to decrease ocular surface inflammation.
    • If blepharitis is caused by Demodex infestation, treatment with weekly lid scrubs with 50% tea tree oil and daily scrubs with tea tree shampoo for a minimum of 6 weeks has been shown to decrease mite load and improve inflammatory responses.
    • Phthiriasis palpebrarum is treated with twice-daily application of petrolatum for 7-10 days. Alternatively, removal of the nits and lice can be accomplished with forceps.  
  • Dacryoadenitis
    • Treatment of acute dacryoadenitis is largely supportive as the disease is usually self-limiting. Use warm compresses and nonsteroidal anti-inflammatory drugs.
    • If the etiology is bacterial, antibiotic treatment with a first-generation cephalosporin should be started.
    • If the etiology is EBV, steroids have been shown to improve the clinical course.
    • For chronic dacryoadenitis, treat the underlying condition.
  • Dacryocystitis
    • Treat with oral antibiotics such as amoxicillin-clavulanic acid or dicloxacillin.
    • In pediatric patients, the obstruction usually resolves by age 9-12 months. Many pediatric ophthalmologists will wait until after this age to probe the ducts to free the obstruction.
    • Dacryocystorhinostomy is the surgical procedure of choice. This procedure allows for the bypassing of the lacrimal duct apparatus as long as the canalicular apparatus is intact.
    • Punctal dilation and nasolacrimal irrigation is contraindicated in the acute stage due to the increased risk of periorbital cellulitis.
  • Canaliculitis
    • Remove concretions with gentle pressure using a cotton swab.
    • Warm compresses
    • Irrigation with penicillin solution to be performed by an ophthalmologist
    • Systemic antibiotics, usually penicillin or amoxicillin for 1-2 weeks
    • Topical antibiotics - Bacitracin or erythromycin: This rarely achieves complete resolution due to inability of antibiotics to penetrate concretions.
    • Canaliculotomy with curettage is the definitive treatment.

Consultations

  • Consider consultation with an ophthalmologist for any patient who may have orbital involvement.
  • Most cases of lacrimal system infections can be managed conservatively. Consultation with an ophthalmologist is indicated if the condition is not resolved within 24-48 hours.



The goals of pharmacotherapy are to eradicate the infection, prevent complications, and reduce morbidity.

Drug Category: Antibiotics, systemic

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Drug NameCephalexin (Keflex)
DescriptionFirst-generation cephalosporin that inhibits bacterial replication by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls.
Resistance occurs by alteration of penicillin-binding proteins. Effective for treatment of infections caused by streptococci or staphylococci, including penicillinase-producing staphylococci. May use to initiate therapy when streptococcal or staphylococcal infection is suspected.
Used orally when outpatient management is indicated.
Has a half-life of 50-80 min. Only 10% is protein bound and greater than 90% recovered unchanged in urine.
Adult Dose250 mg PO qid or 500 mg PO bid for 7-10 d
Pediatric Dose20 mg/kg/d PO divided q8h for 7-10 d; in more serious infections, may increase dose to 40 mg/kg/d; not to exceed 1 g/d
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with aminoglycosides increases nephrotoxic potential
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections, and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug NameAmpicillin and sulbactam (Unasyn)
DescriptionDrug combination of beta-lactamase inhibitor with ampicillin. Interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms.

Provides useful coverage for most organisms associated with dacryocystitis.
Adult Dose1.5 g (1 g ampicillin + 0.5 g sulbactam) to 3 g (2 g ampicillin + 1 g sulbactam) IV/IM q6-8h; not to exceed 4 g/d sulbactam or 8 g/d ampicillin; dosage reduced with renal failure
Pediatric Dose<3 months: Not established
3 months to 12 years: 100-200 mg ampicillin/kg/d (150-300 mg Unasyn) IV divided q6h
>12 years: Administer as in adults; not to exceed 4 g/d sulbactam or 8 g/d ampicillin
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction

Drug NameClindamycin (Cleocin)
DescriptionSemisynthetic antibiotic produced by 7(S)-chloro-substitution of 7(R)-hydroxyl group of parent compound lincomycin. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Widely distributes in the body without penetration of CNS. Protein bound and excreted by the liver and kidneys.
Used for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). As an alternative to sulfonamides, clindamycin may be beneficial when used with pyrimethamine in acute treatment of CNS toxoplasmosis in patients with AIDS.
Adult Dose600 mg PO/IV q6-8h
Pediatric Dose20 mg/kg/d PO/IV divided q6-8h
ContraindicationsDocumented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis
InteractionsIncreases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis by allowing overgrowth of Clostridium difficile

Drug NameSulfamethoxazole and trimethoprim (Bactrim DS, Septra DS)
DescriptionInhibits bacterial growth by inhibiting synthesis of dihydrofolic acid.

Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa.
Adult Dose160 mg TMP/800 mg SMZ PO q12h for 10-14 d
Pediatric Dose<2 months: Do not administer
>2 months: 10-20 mg TMP/kg/d PO/IV divided tid/qid for 14 d
ContraindicationsDocumented hypersensitivity; megaloblastic anemia due to folate deficiency; age <2 mo
InteractionsMay increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly persons; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDo not use during last trimester of pregnancy due to potential toxicity to newborn (eg, jaundice, hemolytic anemia, kernicterus)
Dosage adjustments (adult adjustments)
CrCl (mL/min) 80-50: Recommended IV dose q18h
CrCl 50-10: Recommended IV dose q24h
CrCl <10: Not recommended
HD: 4-5 mg/kg after HD
During peritoneal dialysis: 0.16-0.8 g q48h
Discontinue at first appearance of skin rash or sign of adverse reaction; obtain CBCs frequently; discontinue therapy if significant hematologic changes occur; goiter, diuresis, and hypoglycemia may occur with sulfonamides; prolonged IV infusions or high doses may cause bone marrow depression (if signs occur, give 5-15 mg/d leucovorin); caution in folate deficiency (eg, chronic alcoholics, elderly persons, those receiving anticonvulsant therapy, or those with malabsorption syndrome); hemolysis may occur in G-6-PD deficient individuals; patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment (perform urinalyses and renal function tests during therapy); give fluids to prevent crystalluria and stone formation

Drug NameDoxycycline (Bio-Tab, Doryx, Doxy, Periostat, Vibramycin, Vibra-Tabs)
DescriptionBroad-spectrum, synthetically derived bacteriostatic antibiotic in the tetracycline class. Almost completely absorbed, concentrates in bile, and is excreted in urine and feces as a biologically active metabolite in high concentrations.
Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. May block dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Adult Dose100-200 mg PO qd; some sources recommend using one half of initial dose during second month
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; severe hepatic dysfunction
InteractionsBioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy
PregnancyD - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
PrecautionsPhotosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines

Drug NameVancomycin (Lyphocin, Vancocin, Vancoled)
DescriptionPotent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in the treatment of septicemia and skin structure infections. Indicated for patients who cannot receive, or have failed to respond to penicillins and cephalosporins or have infections with resistant staphylococci. For abdominal penetrating injuries, it is combined with an agent active against enteric flora and/or anaerobes.
To avoid toxicity, current recommendation is to assay vancomycin trough levels after third dose drawn 0.5 h prior to next dosing. Use creatinine clearance to adjust dose in patients diagnosed with renal impairment.
Used in conjunction with gentamicin for prophylaxis in penicillin-allergic patients undergoing gastrointestinal or genitourinary procedures.
Adult Dose500 mg to 2 g/d IV divided tid/qid 7-10 d
1 mg/0.1 mL for intravitreal injection
25 mg/0.5 mL for subconjunctival injection, or
25 mg/mL 1 gtt q5min for 1-7 doses depending on severity, repeat q1h
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity
InteractionsErythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in renal failure, neutropenia; red man syndrome is caused by too rapid IV infusion (dose given over a few min) but rarely happens when dose given IV over 2 h administration or as PO or IP administration; red man syndrome is not an allergic reaction

Drug NameCefuroxime (Ceftin)
DescriptionSecond-generation cephalosporin maintains gram-positive activity that first-generation cephalosporins have and adds activity against Proteus mirabilis, H influenzae, E coli, Klebsiella pneumoniae, and Moraxella catarrhalis.
Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration.
Adult Dose750-1500 mg IV q8h
Adjust dose based on creatinine clearance in renally impaired patients:
CrCl >20: No change
CrCl 10-20: 750 mg q12
CrCl <10: 750 mg q24h
Drug is dialyzable; administer dose after dialysis
Switch to PO dosage form as clinical situation warrants
250-500 mg PO bid
Pediatric Dose25-50 mg/kg IV q8h; switch to PO dosage form as clinical situation warrants
Oral susp not bioequivalent to tab form
Oral susp: 30 mg/kg/d PO divided bid; not to exceed 1000 mg/d
Tab: 125-250 mg PO q12h
ContraindicationsDocumented hypersensitivity
InteractionsDisulfiramlike reactions may occur when alcohol is consumed within 72 h of ingestion; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patient receiving potent diuretics such as loop diuretics; coadministration with aminoglycosides increase nephrotoxic potential
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsBioavailability increases when taken after food; fungal and microorganism overgrowth may occur with prolonged therapy; dosage adjustment for geriatric patients is not necessary; methicillin-resistant staphylococci are resistant to cefuroxime; use with caution in patients with a history of colitis; oral susp contains phenylalanine (do not give in patients with phenylketonuria)

Drug NameNafcillin (Nallpen, Unipen)
DescriptionInitial therapy for suspected penicillin G-resistant streptococcal or staphylococcal infections.
Use parenteral therapy initially in severe infections. Change to PO therapy as condition warrants.
Because of thrombophlebitis, particularly in the elderly persons, administer parenterally only for short term (1-2 d); change to PO route as clinically indicated.
Adult Dose500-2000 mg IV q4-6h; switch to PO dosage form as clinical situation warrants
250-500 mg PO q4-6h, up to 1 g q4-6h for severe infections
Pediatric DoseNot approved for pediatric use; off-label dosing administered as follows:
100 mg/kg/d IV divided q6h
Severe infections: May increase to 200 mg/kg/d IV divided q6h; not to exceed 6-12 g/d; switch to PO dosage form as clinical situation warrants
50-100 mg/kg/d PO divided q6h
ContraindicationsDocumented hypersensitivity
InteractionsAssociated with warfarin resistance when administered concurrently; effects may decrease with bacteriostatic action of tetracycline derivatives
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsTo optimize therapy, determine causative organisms and susceptibility; decrease dose in hepatic dysfunction

Drug NameAmoxicillin and clavulanic acid (Augmentin)
DescriptionTreats bacteria resistant to beta-lactam antibiotics. For children >3 mo, base dosing protocol on amoxicillin content. Because of different amoxicillin/clavulanic acid ratios in 250-mg tab (250/125) vs 250-mg chewable tab (250/62.5), do not use 250-mg tab until child weighs more than 40 kg.
Adult Dose500-875 mg PO bid
Pediatric DoseIn neonates and infants <3 months: 30 mg/kg/d divided PO q12h
In infants >3 months: 45 mg/kg/d PO divided q12h or 40 mg/kg/d divided q8h
Children >40 kg: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with warfarin or heparin increases risk of bleeding
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdminister for minimum of 10 d to eliminate organism; some formulations of Augmentin contain phenylalanine (do not give to phenylketonurics); caution in breastfeeding mothers

Drug NameCefaclor (Ceclor)
DescriptionSecond-generation cephalosporin indicated for infections caused by susceptible gram-positive cocci and gram-negative rods.
Determine proper dosage and route based on condition of patient, severity of infection, and susceptibility of causative organism.
Adult Dose750-1500 mg/d PO divided bid/tid
Pediatric Dose<1 month: Not established
>1 month: 20-40 mg/kg/d PO divided q8-12h; not to exceed 1 g/d
ContraindicationsDocumented hypersensitivity
InteractionsAlcoholic beverages consumed <72 h after ingestion may produce disulfiramlike reactions; may increase hypoprothrombinemic effects of anticoagulants; coadministration with potent diuretics and aminoglycosides (eg, loop diuretics) may increase nephrotoxicity
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsRisk of toxic reactions may be greater in patients with impaired renal function; administer half dose if CrCl is 10-30 mL/min and one-quarter dose if <10 mL/min; fungal and microorganism overgrowth may occur with prolonged therapy

Drug NameTetracycline (Sumycin)
DescriptionTreats gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and, possibly, 50S ribosomal subunit(s).
Adult Dose250 mg PO q6h; alternatively, 500 mg PO q12h
Pediatric Dose<8 years: Not recommended
>8 years: 25-50 mg/kg/d PO divided q6h; not to exceed 3 g/d
ContraindicationsDocumented hypersensitivity; severe hepatic dysfunction
InteractionsBioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of PO contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants
PregnancyD - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
PrecautionsPhotosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; use during tooth development (last one half of pregnancy through age 8 y) can cause permanent tooth discoloration; Fanconilike syndrome may occur with outdated tetracyclines

Drug NameBacitracin (AK-Tracin)
DescriptionPrevents transfer of mucopeptides into growing cell wall, inhibiting bacterial growth.
Adult DoseApply 0.25- to 0.5-inch ribbon q3-4h for 7-10 d into conjunctival sac(s)
Pediatric DoseApply as in adults
ContraindicationsDocumented hypersensitivity; vaccinia, varicella, epithelial herpes simplex keratitis, mycobacterial infections, fungal diseases of the eye; patients using steroid combinations after uncomplicated removal of a corneal foreign body
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsOphthalmic ointments may delay healing of corneal epithelia; in deep-seated infections of the eye, supplement with systemic medications; prolonged use may result in overgrowth of nonsusceptible organisms

Drug NameErythromycin (E-Mycin)
DescriptionMacrolide antibiotic that binds to 50S ribosomal subunit blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Does not affect nucleic acid synthesis.
Indicated for infections caused by susceptible strains of microorganisms and for prevention of corneal and conjunctival infections.
Adult DoseApply 0.5-inch (1.25 cm) ribbon 2-8 times/d depending on severity of infection
Pediatric DoseApply as in adults
ContraindicationsDocumented hypersensitivity; hepatic impairment
InteractionsCoadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis; decreases metabolism of repaglinide, thus increasing serum levels and effects
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in liver disease; estolate formulation may cause cholestatic jaundice; GI side effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur



Further Inpatient Care

  • Further inpatient care is indicated for the treatment of periorbital cellulitis in the pediatric population for the administration of intravenous antibiotics.
  • Further inpatient care is indicated in any patient who is septic or has orbital involvement.

Complications

  • Periorbital cellulitis
    • Toxic shock syndrome
    • Eschar formation leading to scarring
    • Meningitis
    • Orbital cellulitis
    • Necrotizing fasciitis has been described in a case of periorbital cellulitis in an immunocompromised patient
  • Blepharitis
  • Dacryocystitis 
    • Dacryocystitis may be associated with periorbital cellulitis. Rarely, it may be associated with orbital cellulitis or abscess formation. This is usually prevented by the orbital septum, which surrounds the lacrimal sac.
    • Complications may occur during a dacryocystorhinostomy, including hemorrhage, infection, and CSF leakage.
  • Canaliculitis - Epiphora

Prognosis

  • Periorbital cellulitis - With appropriate antibiotics, the prognosis is good.
  • Blepharitis - Typically, this is a chronic disease with waxing and waning of symptoms.
  • Dacryoadenitis
    • Prognosis of the acute form is excellent as it is a self-limiting process.
    • Prognosis of the chronic form depends on the underlying disease process.
  • Dacryocystitis - Success rates for dacryocystorhinostomy are good. External procedures fare better due to the ability to create a larger ostium.
  • Canaliculitis - Prognosis is excellent with definitive treatment by canaliculotomy with curettage.

Patient Education

  • Periorbital cellulitis - For excellent patient education resources see eMedicine's patient education article, Cellulitis.
  • Blepharitis 
    • Blepharitis Fact Sheet is available for purchase from the American Academy of Ophthalmology.
    • The use of eye makeup, especially eyeliner, can cause acute exacerbations by plugging the glands.



Medical/Legal Pitfalls

  • Failure to recognize orbital involvement



  1. Yanoff. Ophthalmology [MD Consult]. 2nd ed. 2004:chap 82, 98.
  2. Brook I. Microbiology of acute sinusitis of odontogenic origin presenting with periorbital cellulitis in children. Ann Otol Rhinol Laryngol. May 2007;116(5):386-8. [Medline].
  3. Noble. Textbook of Primary Care Medicine,. 3rd ed. 2001:(MD Consult) [pg 1693].
  4. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther. Feb 2006;22(1):47-53. [Medline].
  5. Wald ER. Periorbital and orbital infections. Infect Dis Clin North Am. Jun 2007;21(2):393-408, vi. [Medline].
  6. Lee S, Tsirbas A, McCann JD, et al. Mikulicz's disease: a new perspective and literature review. Eur J Ophthalmol. Mar-Apr 2006;16(2):199-203. [Medline].
  7. Lee J, Flanagan JC. Complications associated with silicone intracanalicular plugs. Ophthal Plast Reconstr Surg. Nov 2001;17(6):465-9. [Medline].
  8. Givner LB, Mason EO Jr, Barson WJ, et al. Pneumococcal facial cellulitis in children. Pediatrics. Nov 2000;106(5):E61. [Medline].
  9. Gershon. Krugman's Infectious Diseases of Children. 11th ed. 2004:(MD Consult) [pg 163-4].
  10. Friedlaender MH. Blepharitis, allergy, and dry eye: lumpers and splitters. Ann Ophthalmol (Skokie). Spring 2006;38(1):4-5. [Medline].
  11. Thirumoorthi MC, Asmar BI, Dajani AS. Violaceous discoloration in pneumococcal cellulitis. Pediatrics. Oct 1978;62(4):492-3. [Medline].
  12. Carter SR. Eyelid disorders: diagnosis and management. Am Fam Physician. Jun 1998;57(11):2695-702. [Medline].
  13. Farpour B, McClellan KA. Diagnosis and management of chronic blepharokeratoconjunctivitis in children. J Pediatr Ophthalmol Strabismus. Jul-Aug 2001;38(4):207-12. [Medline].
  14. Wald ER. Periorbital and orbital infections. Pediatr Rev. Sep 2004;25(9):312-20. [Medline].
  15. Long. Principles and Practice of Pediatric Infectious Diseases (MD Consult).
  16. Givner LB. Periorbital versus orbital cellulitis. Pediatr Infect Dis J. Dec 2002;21(12):1157-8. [Medline].
  17. Charalampidou S, Connell P, Fennell J, et al. Preseptal cellulitis caused by community acquired methicillin resistant Staphylococcus aureus (CAMRSA). Br J Ophthalmol. Dec 2007;91(12):1723-4. [Medline].
  18. Ambati BK, Ambati J, Azar N, et al. Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology. Aug 2000;107(8):1450-3. [Medline].
  19. Donahue SP, Schwartz G. Preseptal and orbital cellulitis in childhood. A changing microbiologic spectrum. Ophthalmology. Oct 1998;105(10):1902-5; discussion 1905-6. [Medline].
  20. Schwartz GR, Wright SW. Changing bacteriology of periorbital cellulitis. Ann Emerg Med. Dec 1996;28(6):617-20. [Medline].
  21. Green JA, Lim J, Barkham T. Neisseria gonorrhoeae: a rare cause of preseptal cellulitis?. Int J STD AIDS. Feb 2006;17(2):137-8. [Medline].
  22. Chand DV, Hoyen CK, Leonard EG, et al. First reported case of Neisseria meningitidis periorbital cellulitis associated with meningitis. Pediatrics. Dec 2005;116(6):e874-5. [Medline].
  23. Porras MC, Martínez VC, Ruiz IM, et al. Acute cellulitis: an unusual manifestation of meningococcal disease. Scand J Infect Dis. 2001;33(1):56-9. [Medline].
  24. Lewis FM, Chernak E, Goldman E, et al. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis. Jan 2006;12(1):134-7. [Medline].
  25. Fillmore GL, Ward TP, Bower KS, et al. Ocular complications in the Department of Defense Smallpox Vaccination Program. Ophthalmology. Nov 2004;111(11):2086-93. [Medline].
  26. Raina UK, Jain S, Monga S, et al. Tubercular preseptal cellulitis in children: a presenting feature of underlying systemic tuberculosis. Ophthalmology. Feb 2004;111(2):291-6. [Medline].
  27. Artac H, Silahli M, Keles S, et al. A rare cause of preseptal cellulitis: anthrax. Pediatr Dermatol. May-Jun 2007;24(3):330-1. [Medline].
  28. Sacca SC, Pascotto A, Venturino GM, et al. Prevalence and treatment of Helicobacter pylori in patients with blepharitis. Invest Ophthalmol Vis Sci. Feb 2006;47(2):501-8. [Medline].
  29. Kheirkhah A, Casas V, Li W, et al. Corneal manifestations of ocular demodex infestation. Am J Ophthalmol. May 2007;143(5):743-749. [Medline].
  30. Thappa DM, Karthikeyan K, Jeevankumar B. Phthiriasis palpebrarum. Postgrad Med J. Feb 2003;79(928):102. [Medline].
  31. Rhem MN, Wilhelmus KR, Jones DB. Epstein-Barr virus dacryoadenitis. Am J Ophthalmol. Mar 2000;129(3):372-5. [Medline].
  32. Mills DM, Bodman MG, Meyer DR, et al. The microbiologic spectrum of dacryocystitis: a national study of acute versus chronic infection. Ophthal Plast Reconstr Surg. Jul-Aug 2007;23(4):302-6. [Medline].
  33. Anand S, Hollingworth K, Kumar V, et al. Canaliculitis: the incidence of long-term epiphora following canaliculotomy. Orbit. Mar 2004;23(1):19-26. [Medline].
  34. Moscato EE, Sires BS. Atypical canaliculitis. Ophthal Plast Reconstr Surg. Jan-Feb 2008;24(1):54-5. [Medline].
  35. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. Apr 2003;121(4):491-9. [Medline].
  36. Lamoreau KP, Fanciullo LM. Pott's Puffy Tumor Mimicking Preseptal Cellulitis. Clin Exp Opt 2007; Published early online. Accessed 15 March, 2008.
  37. Swann PG, Weir J. Is it blepharitis?. Clin Exp Optom. Mar 2005;88(2):113-4. [Medline].
  38. Boruchoff SA, Boruchoff SE. Infections of the lacrimal system. Infect Dis Clin North Am. Dec 1992;6(4):925-32. [Medline].
  39. Charles NC, Lisman RD, Mittal KR. Carcinoma of the lacrimal canaliculus masquerading as canaliculitis. Arch Ophthalmol. Mar 2006;124(3):414-6. [Medline].
  40. Howe L, Jones NS. Guidelines for the management of periorbital cellulitis/abscess. Clin Otolaryngol Allied Sci. Dec 2004;29(6):725-8. [Medline].
  41. Tost F, Bruder R, Clemens S. Clinical diagnosis of chronic canaliculitis by 20-MHz ultrasound. Ophthalmologica. 2000;214(6):433-6. [Medline].
  42. O'Donnell BA, Clement CI. Assessing patients with epiphora who are patent to syringing: clinical predictors of response to dacryocystorhinostomy. Ophthal Plast Reconstr Surg. May-Jun 2007;23(3):173-8. [Medline].
  43. Vu BL, Dick PT, Levin AV, et al. Development of a clinical severity score for preseptal cellulitis in children. Pediatr Emerg Care. Oct 2003;19(5):302-7. [Medline].
  44. American Academy of Ophthalmology. Preferred Practice Patterns: Blepharitis. Available at: http://one.aao.org. Accessed March 14, 2008.
  45. Viswalingam M, Rauz S, Morlet N, et al. Blepharokeratoconjunctivitis in children: diagnosis and treatment. Br J Ophthalmol. Apr 2005;89(4):400-3. [Medline].
  46. Aburn NS, Sullivan TJ. Infectious mononucleosis presenting with dacryoadenitis. Ophthalmology. May 1996;103(5):776-8. [Medline].
  47. American Academy of Ophthalmology. Preferred Practice Patterns: Blepharitis. Accessed May 14, 2006. [Full Text].
  48. American Academy of Ophthalmology. Available at: https://secure3.aao.org/store/common/index.cfm. Accessed March 15, 2008.
  49. Ataullah S, Sloan B. Acute dacryocystitis presenting as an orbital abscess. Clin Experiment Ophthalmol. Feb 2002;30(1):44-6. [Medline].
  50. Baylin EB, Gladstone GJ. Endoscopic lacrimal surgery. Otolaryngol Clin North Am. Oct 2005;38(5):1099-107. [Medline].
  51. Cummings C, Haughey B, Thomas R, et al. Cummings Otolaryngology. In: Head and Neck Surgery. 4th ed. 2005:771.
  52. Elwood ET, Sommerville DN, Murray JD. Periorbital necrotizing fasciitis. Plast Reconstr Surg. Dec 2007;120(7):107e-111e. [Medline].
  53. Greenberg MF, Pollard ZF. The red eye in childhood. Pediatr Clin North Am. Feb 2003;50(1):105-24. [Medline].
  54. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther. Feb 2006;22(1):47-53. [Medline].
  55. Varma D, Chang B, Musaad S. A case series on chronic canaliculitis. Orbit. Mar 2005;24(1):11-4. [Medline].
  56. Yanoff. Ophthalmology. 2nd ed. 2004:761.

Periorbital Infections excerpt

Article Last Updated: Nov 18, 2008